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Renal Replacement Therapy in Healthy Adult Horses
Abstract
Background
Renal replacement therapy (RRT) has been implemented extensively in people to facilitate recovery from
acute renal failure (ARF). RRT has not been explored in horses, but might provide a further treatment option
in horses with ARF.
Objective
To investigate efficacy and safety of RRT in horses.
Animals
Five healthy adult horses.
Methods
A prospective study was performed on horses restrained in stocks and intravenously connected to a
commercial RRT machine to allow continuous venovenous hemodiafiltration to be performed for 6 hours.
The RRT machine was set at the following flow rates: blood flow rate 250 mL/min; dialysate rate 3,000 mL/h;
prefilter replacement pump 3,000 mL/h; and postfilter replacement pump rate 2,000 mL/h. Balanced
electrolyte solution was used as dialysate and replacement fluid. Heart rate, respiratory rate, body temperature,
direct arterial blood pressure, urine output, and various clinicopathologic parameters were measured over the
study period.
Results
Renal replacement therapy was successfully performed in horses, resulting in a mean creatinine clearance of
0.127 mL/kg/min (68.9 mL/min) and urea reduction ratio of 24%. No adverse effects were detected although
a significant decrease in rectal temperature was observed (P ≤ .007). A significant increase in serum
phosphorus (P ≤ .001) and decrease in BUN (P < .001) were also noted. A significant prolongation of
prothrombin (P < .01) and partial thromboplastin time (P < .0001) were observed along with a decrease in
platelet count (P ≤ .04).
Conclusions and Clinical Importance
Renal replacement therapy can safely and effectively be used in adult horses.
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Renal Replacement Therapy in Healthy Adult Horses
D.M. Wong, D. Witty, C.J. Alcott, B.A. Sponseller, C. Wang, and K. Hepworth
Background: Renal replacement therapy (RRT) has been implemented extensively in people to facilitate recovery from
acute renal failure (ARF). RRT has not been explored in horses, but might provide a further treatment option in horses
with ARF.
Objective: To investigate eﬃcacy and safety of RRT in horses.
Animals: Five healthy adult horses.
Methods: A prospective study was performed on horses restrained in stocks and intravenously connected to a commer-
cial RRT machine to allow continuous venovenous hemodiaﬁltration to be performed for 6 hours. The RRT machine was
set at the following ﬂow rates: blood ﬂow rate 250 mL/min; dialysate rate 3,000 mL/h; preﬁlter replacement pump
3,000 mL/h; and postﬁlter replacement pump rate 2,000 mL/h. Balanced electrolyte solution was used as dialysate and
replacement ﬂuid. Heart rate, respiratory rate, body temperature, direct arterial blood pressure, urine output, and various
clinicopathologic parameters were measured over the study period.
Results: Renal replacement therapy was successfully performed in horses, resulting in a mean creatinine clearance of
0.127 mL/kg/min (68.9 mL/min) and urea reduction ratio of 24%. No adverse eﬀects were detected although a signiﬁcant
decrease in rectal temperature was observed (P  .007). A signiﬁcant increase in serum phosphorus (P  .001) and
decrease in BUN (P < .001) were also noted. A signiﬁcant prolongation of prothrombin (P < .01) and partial thrombo-
plastin time (P < .0001) were observed along with a decrease in platelet count (P  .04).
Conclusions and Clinical Importance: Renal replacement therapy can safely and eﬀectively be used in adult horses.
Key words: Creatinine clearance; Dialysis; Eﬄuent; Heparin; Renal failure.
Acute renal failure (ARF) is characterized by amarked decrease in glomerular ﬁltration rate and
manifests clinically as abrupt and sustained increases
in BUN and creatinine concentrations along with
derangements in ﬂuid, electrolyte, and acid–base
homeostasis.1 Conventional treatment principles of
ARF include reversal of inciting or underlying cause,
judicious administration of IV ﬂuids, and correction of
electrolyte and acid–base abnormalities.2,3 In people
and companion animals, renal replacement therapy
(RRT) may be instituted if ARF remains refractory to
conventional treatment to the extent that 50–70% of
human ICU patients with ARF will currently receive
RRT.4–8 The use of RRT in horses is not well
described, but successful outcomes have been reported
using intermittent hemodialysis (IHD) in an adult
horse with myoglobin-induced ARF and a foal with
oxytetracycline-induced ARF.9,10 In addition, case
reports have described the use of peritoneal dialysis to
facilitate recovery of horses with ARF.11–13
Renal replacement therapy is a blood puriﬁcation
modality that has become the treatment of choice
for ARF in some medical facilities.7,8 Renal indica-
tions for instituting RRT in people include reduced
glomerular ﬁltration rates leading to solute imbalance
or oliguria resulting in extracellular ﬂuid volume over-
load that does not respond to other forms of treat-
ment.14,15 Nonrenal indications for RRT include
facilitating clearance of various drugs, toxins, toxic
metabolites, or inﬂammatory cytokines.6,15,16 RRT can
be broadly categorized into continuous renal replace-
ment therapy (CRRT) and (IHD). CRRT is similar to
IHD in that the patient’s blood is divided among and
passed through thousands of straw-like semipermeable
membranes contained within a dialyzer. In addition to
diﬀusion principles that promote blood puriﬁcation in
IHD, CRRT has the ability to use convection (solvent
drag) and adsorption (adhesion) to promote blood
puriﬁcation.5,7,8 Other advantages of CRRT over IHD
include the ability to employ a slow, continuous, and
From the Department of Veterinary Clinical Sciences, Lloyd
VeterinaryMedical Center, Iowa State University, Ames, IA (Wong,
Alcott, Sponseller, Hepworth); Gambro Products, Lakewood, CO
(Witty); and the Department of Veterinary Production Ani-mal
Medicine, Iowa State University, Ames, IA (Wang).
Corresponding author: Dr D.M. Wong, Department of Veterinary
Clinical Sciences, Lloyd Veterinary Medical Center, Iowa State
University, Ames, IA; e-mail: dwong@iastate.edu.
Submitted April 18, 2012; Revised November 27, 2012;
Accepted January 7, 2013.
Copyright © 2013 by the American College of Veterinary Internal
Medicine
10.1111/jvim.12049
Abbreviations:
ACT activated clot time
ARF acute renal failure
Ca calcium
Cl chloride
CrCl creatinine clearance
CRI constant rate infusion
CRRT continuous renal replacement therapy
HCO3 bicarbonate
IHD intermittent hemodialysis
K potassium
Kt/V urea clearance over time
Na sodium
Phos phosphorus
PT prothrombin time
PTT partial thromboplastin time
RRT renal replacement therapy
URR urea reduction ratio
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gradual puriﬁcation process, which provides better
control of blood pressure as well as electrolyte and
acid–base balance.4,5,16 The continuous nature of
CRRT allows the modality to more closely mimic the
function of the healthy kidney and the convective pro-
cess of CRRT allows more eﬀective removal of larger
molecules with limited diﬀusibility.4,5,16 A technical
advantage of CRRT is the ability to use prepackaged
sterile ﬂuids as compared with hemodialysis which
requires signiﬁcant amounts of pure dialysate that
must be produced on-site with specialized water treat-
ment facilities.
Despite advancements in equine critical care, investi-
gation of RRT has not been described. The lack of
consideration of RRT in horses may be a result of the
perceived high cost of equipment or labor-intensive
nature of instituting treatment. With the advent of
more cost-eﬀective equipment and demand for
advanced treatment, RRT may be a realistic treatment
option for the equine patient with renal failure. The
objectives of this study were to develop a protocol by
which RRT can be implemented, utilizing a commer-
cial CRRT machine, and to evaluate the safety and
eﬃcacy of RRT in adult horses. Of note, although a
CRRT machine was utilized for this study, therapy, as
it pertains to this study, will be referred to as RRT as
the treatment period was only 6 hours, and not techni-
cally continuous (ie, 24+ continuous hours).
Materials and Methods
Horses
Five healthy adult mares (age range 3–11 years) from the Iowa
State University teaching herd were used after the study protocol
was approved by the University Animal Care and Use Commit-
tee. The mean body weight was 544 kg (range 486–609 kg).
Horses were housed individually in box stalls and allowed to
acclimatize to the environment 24 hours before experimentation.
Health status was based on the results of physical examination
and evaluation of a complete blood count and biochemistry pro-
ﬁle performed 24 hours before experimentation. Horses were fed
free choice grass hay and had unlimited access to water.
Instrumentation
On the morning of experimentation, each horse was sedated
with xylazinea (0.3 mg/kg, IV), the hair was clipped, skin asepti-
cally prepared, and local anesthetic administered SC over 4 sites
including the right jugular vein, left jugular vein, cephalic vein,
and transverse facial artery for intravenous or intra-arterial cath-
eter placement. A 14-gauge 5.25-inch over-the-needle polyure-
thane catheterb was inserted into the right jugular vein to allow
for sampling of blood during the experiment. To provide a con-
tinuous rate infusion (CRI) of sedation, a 16-gauge 3-inch over-
the-needle polyurethane catheterc was inserted into the right
cephalic vein to allow for administration of a detomidine CRI.
A 20-gauge, 1.5-inch over-the-needle polyurethane catheterd was
inserted into the transverse facial artery to allow for arterial
blood pressure monitoring. A 14 French over-the-wire double
lumen dialysis cathetere was placed in the left jugular vein. All
catheters were ﬂushed with heparinized saline and secured in
place by suturing to the skin. Lastly, a 20 French indwelling
urinary catheterf was placed aseptically into the urinary bladder
and connected to a closed urine collection system.
Monitoring Vital Parameters
One hour after instrumentation was completed, the transverse
facial artery catheter was interfaced with an arterial blood pres-
sure monitorg and baseline arterial blood pressure (mean, sys-
tolic, diastolic) was recorded (Time 0). In addition, baseline heart
rate, respiratory rate, and rectal temperature values were col-
lected before initiation of the detomidine CRI. An ECGg was
attached to the horse utilizing a base-apex lead to monitor heart
rhythm. Vital parameters (heart rate, respiratory rate, rectal tem-
perature, arterial blood pressure) were measured at 0.5, 1, 1.5, 2,
2.5, 3, 3.5, 4, 5, 6, 12, and 24 hours.
Continuous IV Sedation
Detomidineh (50 mg) was diluted with 0.9% sodium chloride
to a concentration of 1 mg/mL. Immediately after collection of
baseline data (Time 0), a loading dose of 8.4 lg/kg of detomidine
was administered as an IV bolus. Subsequently, detomidine was
administered, utilizing an electronic syringe pump, at a dose of
0.5 lg/kg/min for 15 minutes, which was decreased to 0.3 lg/kg/
min for 15 minutes and decreased again to 0.15 lg/kg/min there-
after.17
Anticoagulation
A baseline prothrombin time (PT), partial thromboplastin time
(PTT), and platelet count were measured after instrumentation
was complete (Time 0). Immediately before the commencement
of RRT (ie, immediately after detomidine bolus), a bolus dose of
100 IU/kg of sodium heparini was administered IV through the
dialysis catheter to provide systemic anticoagulation; subse-
quently, a CRI of heparin (50 IU/kg/h) was initiated, as previ-
ously described.18 Anticoagulation was monitored by
measurement of PT, PTT, and platelet count every hour during
RRT and then 6 and 12 hours after discontinuation of RRT and
heparin CRI.
Experimental Protocol
Each horse was placed in stocks and administered the loading
dose of detomidine, immediately followed by the CRI of detomi-
dine, as described. The loading dose of heparin was administered
and the RRT procedure was initiated. A commercial CRRT
machinej that incorporates an extracorporeal circuit with an
integrated 1.5 m2 ﬁlterk was utilized. The CRRT machine mode
was set to deliver continuous venovenous hemodiaﬁltration for
6 hours with the blood ﬂow rate set to remove 250 mL of blood/
min. The dialysate rate was set at 3,000 mL/h with the preﬁlter
replacement pump set at 3,000 mL/h and the postﬁlter replace-
ment pump rate set at 2,000 mL/h. The CRRT machine was set
to produce no net change (gain or loss) in patient ﬂuid balance
(ie, dialysate plus pre- and postﬁlter replacement ﬂuids were
automatically added and removed within the dialysis circuit and
in total, equaled the volume of eﬄuent; Fig 1). The eﬄuent was
comprised of a combination of the dialysate and pre- and postﬁl-
ter replacement ﬂuids. Balanced electrolyte solutionl was used as
the dialysate and replacement ﬂuid.
Free choice availability to hay and water was provided during
the 6-hour experimental period, vital parameters were measured
every 30 minutes, and the ECG was constantly monitored for the
presence of cardiac arrhythmias. In addition, 12 mL of blood was
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collected at baseline (Time 0) from the right jugular vein catheter
and placed into EDTA (platelet count), sodium citrate (PT, PTT),
and clot tubes (BUN, creatinine, sodium [Na], potassium [K],
chloride [Cl], bicarbonate [HCO3], calcium [Ca], phosphorus
[Phos]) to measure various biochemical parameters. Subsequently,
12 mL of blood was collected every hour (1, 2, 3, 4, 5, and
6 hours) to measure the aforementioned blood parameters during
RRT. Eﬄuent was collected at 1, 2, 3, 4, 5, and 6 hours and
placed in sterile tubes for measurement of aforementioned bio-
chemical parameters. Urine output was measured hourly over the
study period. To evaluate eﬃcacy of RRT, the creatinine clear-
ance (CrCl), urea reduction ratio (URR), and urea clearance over
time (Kt/V) were calculated using the following formulas:
Creatinine clearance (mL/min) of the eﬄuent ﬂuid19:
CrCl ¼ Ultrafiltrate [Cr]
Plasma [Cr]
Dialysate output [mL]
Time [minute]
 
Creatinine clearance based on body weight (CrCl; mL/kg/min)
of the eﬄuent ﬂuid20:
CrCl ¼
Ultrafiltrate [Cr]
Plasma [Cr]
Dialysate output [mL]
Time [minute]
Body weight (kg)
0
BB@
1
CCA
Urea reduction ratio (%) of the blood21:
URR ¼ preBUN postBUN
preBUN
100
Urea clearance over time, normalized to patient volume of dis-
tribution (Kt/V):
Urea clearance over time ¼ Kt=V5
K = urea clearance (mL/min), t = time (estimated for 24 hours
or 1,440 minutes), V = patient’s volume of distribution (esti-
mated by 0.6 9 BWT).
Statistical Analysis
Sample mean  SD values were calculated for each response
variable. Data were analyzed using a repeated measures analysis
of variance (ANOVA) model, with time as a ﬁxed eﬀect and
horse as the subject of repeated measures. PTT was rank trans-
formed before analyses because of upper-censoring at 245 sec-
onds by the analyzer. Diﬀerence in mean response among times
was assessed using an overall F-test followed by Tukey’s t-tests
for posthoc pairwise comparison. P-values  .05 were consid-
ered signiﬁcant.
Results
Monitored Vital Parameters
Heart rate was signiﬁcantly lower at 2.5, 4, and
5 hours (P < .05), whereas respiratory rate was signiﬁ-
cantly lower at time 2.5 hours (P < .05) when compared
with baseline (Table 1). Rectal temperature was signiﬁ-
cantly lower at 3, 3.5, 4, 5, and 6 hours (P  .007)
when compared with baseline. No signiﬁcant diﬀerences
were detected in systolic, diastolic, or mean blood pres-
sure at any time, when compared with baseline values.
Second-degree atrioventricular block occurred (2–4 inci-
dences/min) in 2 horses (Horse 2, 2–6 hours; Horse 4, 2
–4 hours), whereas occasional ventricular premature
contractions occurred (2–6 incidences/min) in 2 other
horses (Horse 1, 4 hours; Horse 3, 6 hours) upon evalu-
ation of the heart rhythm via ECG. Normal sinus
rhythm was present 24 hours after initiation of study.
Continuous IV Sedation
All horses tolerated the detomidine CRI with no
major discomfort or anxiety subjectively detected during
the RRT procedure. Horses appeared to recover from
sedation within 30 minutes of discontinuing the CRI.
Anticoagulation
The PT was signiﬁcantly prolonged (P < .01) at
2–6 hours, whereas the PTT was signiﬁcantly pro-
longed (P < .0001) at 1–12 hours when compared with
baseline measurements (Table 2); no statistical diﬀer-
ences in PT or PTT were detected 24 hours after initia-
tion of RRT, when compared with baseline. The
platelet count was signiﬁcantly lower (P  .04) at
2–6 hours when compared with baseline; no statistical
diﬀerence was detected at 12 and 24 hours when com-
pared with baseline. Hematoma formation at either
the left jugular vein (2 horses) or transverse facial
artery (1 horse) occurred upon removal of the catheter,
despite prolonged external pressure being applied to
the site of catheter insertion. No long-term detrimental
eﬀects of anticoagulation treatment were noted.
Serum and Eﬄuent Biochemistry Parameters
During the 6-hour CRRT procedure, a signiﬁcant
increase (P  .001) in serum phosphorus concentra-
tion was detected at 2–6 hours, when compared with
A
B
C
D
E
Fig 1. Schematic diagram of dialysis circuit used for RRT in 5
horses. (A) Blood is actively extracted from the patient via a
peristaltic pump at selected rate (ie, 250 mL/min) and (B) preﬁl-
ter ﬂuids are incorporated with the blood (ie, 3,000 mL/h). (C)
The direction of ﬂow of the dialysate (ie, 3,000 mL/h) travels in
the opposite direction of the blood. (D) Postﬁlter ﬂuids
(3,000 mL/h) are also incorporated. (E) The eﬄuent pump con-
trols the amount of eﬄuent collected; the eﬄuent is a combina-
tion of dialysate, pre- and postﬁlter ﬂuids, and controls the net
ﬂuid gain or ﬂuid loss in the patient.
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baseline (Table 2). A signiﬁcant decrease (P < .001) in
BUN concentration was also detected at 1–6 hours,
when compared with baseline. No signiﬁcant diﬀer-
ences in serum sodium, potassium, chloride, bicarbon-
ate, calcium, or creatinine concentrations were
detected at any time point, when compared with base-
line values. No signiﬁcant diﬀerences in the concentra-
tion of sodium, potassium, chloride, bicarbonate,
calcium, phosphorus, or creatinine concentration were
detected in the eﬄuent at any time with the exception
of a signiﬁcant decrease in eﬄuent urea nitrogen
(P = .03) detected at Time 6 hours when compared
with 1 hour (Table 3).
RRT Parameters
In general, horses tolerated the high rate of blood
extraction (250 mL/min) from the dialysis catheter
during the experimental period without complication.
Occasional (1–2 episodes/h) brief periods (1–3 minutes)
of high negative pressure were detected within the dial-
ysis circuit when the jugular vein would collapse on
the dialysis catheter. After a momentary pause of the
dialysis procedure, RRT was reinitiated without diﬃ-
culty. The mean hourly eﬄuent produced and mean
hourly dialysate, replacement, and pre- and postﬁlter
replacement ﬂuid volumes utilized during the RRT ses-
sion in the 5 horses are presented in Table 4. The
mean hourly CrCl is also reported in Table 4 with an
overall mean CrCl (Times 1–6 hours) of 0.127 mL/kg/
min (68.9 mL/min). Likewise, the mean hourly Kt/V is
reported in Table 4 with an overall mean Kt/V (Times
1–6 hours) of 0.308. The mean URR was 24% over
the 6 hours CRRT period.
Discussion
Acute renal failure is a serious and life-threatening
disorder in horses with numerous causes.2,3 Renal
replacement therapies have been used in people and
companion animals to help improve the outcome of
ARF4,5, whereas nonrenal indications for RRT include
removal of inﬂammatory mediators (ie, cytokines) and
treatment of toxicities or ﬂuid overload.6 In compan-
ion animals, CRRT has been used successfully to treat
ARF, leptospirosis, tumor lysis syndrome, heatstroke,
pre- and postsurgical ureteral obstruction, and various
toxicities.5 To date, RRT has not been widely used in
horses. In the study here, RRT was successfully
administered to 5 healthy mares and provided moder-
ate eﬃcacy as a RRT in conjunction with minor alter-
ations in various vital parameters. In light of this
information, RRT has the potential to become a viable
adjunct treatment for ARF in horses.
Signiﬁcant changes in monitored vital parameters
were observed in the study presented here, although
none were considered life threatening. Heat loss com-
monly occurs in people during RRT consequently pro-
moting hypothermia.22,23 Similarly, in the study here, a
progressive and signiﬁcant decrease in rectal tempera-
ture was observed during the 6 hour procedure.
Hypothermia results from extracorporeal blood ﬂow
that is exposed to a cooler ambient environment and
RRT ﬂuids, thus returning the patient’s blood at a
lower temperature. Temperature loss is increased when
faster dialysate rates or slower extracorporeal blood
ﬂow rates are implemented.22 Intravenous ﬂuid warm-
ers are utilized in some dialysis facilities, but a
randomized controlled trial did not demonstrate main-
tenance of normothermia with the use of IV ﬂuid
warmers in people.23 Another potential variable that
may have contributed to hypothermia observed in this
study was the CRI of detomidine.24 While the decrease
in rectal temperature in this study was mild, monitor-
ing body temperature during RRT is prudent and
allows detection of hypothermia and implementation
of methods to facilitate warming of the patient (eg,
blankets, warmed ﬂuids, higher ambient temperatures).
Rectal temperature returned to within normal intervals
within 6 hours of discontinuation of RRT in this
Table 1. Mean  standard deviation values of various physical examination parameters and urine output mea-
sured from 5 horses over a 6 hour period of renal replacement therapy.
Time (hours) HR (BPM) RR (BRM) Temp (°F) SAP (mmHg) DAP (mmHg) MAP (mmHg) Urine Output (mL)
0 41  5 20  8 99.4  1 145  14 94  8 112  9 0
0.5 34  5 13  3 99.2  1 154  31 101  18 123  24 200  170
1 32  8 11  3 99.1  0.8 150  41 105  25 124  31 144  43
1.5 32  6 13  2 99.1  0.8 147  23 95  15 113  22 357  387
2 34  6 11  3 98.8  1.1 134  24 94  9 111  15 1,192  856
2.5 30  8a 9  3a 98.5  1.2 133  17 95  12 113  14 2,330  1,667
3 32  7 11  3 98.1  0.9a 131  17 92  8 104  13 1,360  764
3.5 31  9 11  2 98.0  1.0a 134  14 95  10 104  15 1,325  922
4 30  7a 13  3 97.7  1.2a 139  37 85  15 102  15 2,026  1,807
5 31  7a 11  2 98.0  1.2a 124  24 82  16 96  19 2,310  1,567
6 37  12 13  4 97.3  0.8a 123  26 75  16 94  19 1,730  1,823
12 42  2 15  3 100.6  1.8 NP NP NP NP
24 37  3 21  9 99.5  0.3 NP NP NP NP
HR, heart rate; RR, respiratory rate; Temp, rectal temperature; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP,
mean arterial pressure; NP, not performed.
aWithin a column, signiﬁcantly diﬀerent from baseline (Time 0) measurement.
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study. Other signiﬁcant changes included modest
decreases in heart and respiratory rates at variable
times. These changes were not perceived as clinically
important and were likely related to the CRI of de-
tomidine, which is known to cause cardiovascular and
respiratory depression.20,25–27 In addition, transient ar-
rhythmias were noted during RRT. A low incidence of
arrhythmias (<5%) has been reported in people treated
with CRRT, but these patients tend to have signiﬁcant
underlying medical disorders (ie, sepsis, acidemia, elec-
trolyte derangements).28 The authors suggest that the
arrhythmias noted in this study were related to detom-
idine administration, as this drug has been associated
with second-degree atrioventricular block, sinoatrial
block, premature supraventricular depolarization, and
premature ventricular contractions26,27; in addition,
normal heart rhythm was recorded shortly after dis-
continuation of detomidine CRI. Alternatively, the ar-
rhythmias observed may have been incidental
observations as second-degree atrioventricular block,
and ventricular premature contractions have been doc-
umented in clinically healthy horses over a continuous
24-hour ECG monitoring period.29
During any form of hemodialysis, blood traveling
through the dialysis circuit undergoes shear stress from
rapid removal through the IV catheter and is also
exposed to various exogenous substances, including IV
catheters, tubing, and dialysis chambers and mem-
branes, all activating, to varying degrees, the coagula-
tion cascade and platelets. Thus, 1 important
component in RRT is provision of anticoagulation to
prevent, or at least slow, clotting of dialysis membrane
ﬁlters. Anticoagulation is accomplished via administra-
tion of heparin or citrate.30 In the study reported here,
100 IU/kg of heparin was administered as a bolus fol-
lowed by a CRI of 50 IU/kg/h, as previously
described.18 A signiﬁcant prolongation of the PT and
PTT was observed between 1 and 6 hours when com-
pared with baseline; these parameters returned to base-
line values within 18 hours after discontinuation of
heparin CRI. The exact prolongation of PTT in this
study could not be determined as samples exceeded the
upper limit of detection (>245 seconds); however, pre-
vious reports of heparin administration at the same
dose resulted in a mean  SD PTT prolongation of
335  93 to 684  334 seconds during a 6 hour per-
iod.18 In addition, a signiﬁcant decrease in platelet
count was observed between 2 and 6 hours. Heparin
administration in horses, at doses of 100, 240, and
320 IU/kg SC every 12 hours, has been reported to
result in reduction in platelet counts of similar magni-
tude as that observed in this study.31,32 The exact
mechanism of heparin-associated thrombocytopenia in
horses remains unknown, but a similar phenomenon
has been documented in people. Heparin-induced
thrombocytopenia (Type 1) in people is a nonimmuno-
genic process associated with an early, limited, and
self-recovering platelet decrease.33 Heparin-induced
thrombocytopenia (Type 2) is associated with a major
drop in platelets caused by the formation of platelet-
activating antibodies against complexes of plateletT
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factor 4 and heparin.33 Likely a combination of
heparin-associated thrombocytopenia, shear forces,
and exposure of platelets to exogenous substances
contributed to the decreased platelet count.
The dose of heparin in this study appeared to be
appropriate for prevention of excessive clot formation
within the dialyzer. However, hematoma formation
was observed at the catheter site after removal of the
catheters in the transverse facial artery and left jugular
vein in some horses. The combination of prolonged
PT and PTT and either high blood pressure at the
arterial site or large bore catheter size at the left
jugular site likely made these sites vulnerable to bleed-
ing and hematoma formation. During CRRT in peo-
ple, heparin dosage is typically adjusted periodically
(ie, every 6 hours) to a targeted PTT prolongation of
1.3–2 times the reference value for PTT.34,35 The
authors speculate that lower doses of heparin may be
adequate to provide anticoagulation during RRT in
horses; however, future studies that evaluate the hepa-
rin dose more rigidly are needed.
A signiﬁcant decrease in BUN and increase in serum
phosphorus was detected in this study. Urea, a small-
molecular-weight metabolite (60 Da) produced from the
metabolism of nitrogen, is used as a surrogate index for
unidentiﬁed or unmeasured small-molecular-weight
solutes that may contribute to uremia.21 As one of the
primary objectives of RRT is to remove uremic toxins,
it is not unexpected to observe a decrease in BUN, par-
ticularly in light of the fact that the dialysate and
replacement ﬂuids are devoid of urea. What is peculiar
is the moderate increase in serum phosphorus noted
between 2 and 6 hours. Hyperphosphatemia is com-
monly observed in acute kidney injury in people and
consequently phosphorus is not a standard component
of dialysate or replacement ﬂuids in CRRT.36 It is there-
fore common to observe hypophosphatemia rather than
hyperphosphatemia during CRRT.36 The serum phos-
phorus remained within reference limits in the horses in
this study, but monitoring of serum electrolytes and
minerals is indicated in horses subjected to RRT. The
exact reason for the increase in serum phosphorus con-
centrations in the horses evaluated here remains
obscure.
Standard methods to evaluate treatment adequacy
and eﬃcacy of RRT include creatinine clearance, urea
reduction ratio, and urea clearance over time. Creati-
nine clearance represents the volume of blood cleared
of creatinine per minute exertion of urine, or in the
case of RRT, eﬄuent.16 The mean CrCl over the
6 hour RRT period was 68.9 mL/min or 0.127 mL/kg/
min. In a reported equine case investigating peritoneal
dialysis, the CrCl in a horse with ARF treated with
intermittent or continuous peritoneal dialysis was
12.5 mL/min (0.0322 mL/kg/min) and 40.9 mL/min
(0.1054 mL/kg/min), respectively, which is approxi-
Table 3. Mean  standard deviation values of various biochemical parameters measured in the eﬄuent from 5
horses over a 6 hour period of renal replacement therapy.
Time
(hours)
Na+
(mEq/L)
K+
(mEq/L)
Cl
(mEq/L)
HCO3
(mEq/L)
Ca++
(mEq/L)
Phos
(mg/dL)
EUN
(mg/dL)
Cr
(mg/dL)
1 133  1 3 6  0.2 102  0.8 24.6  0.5 5.7  0.4 1.9  0.3 9.2  0.8 0.9  0.1
2 134  1.8 3.7  0.2 102  0.5 26  1.6 5.6  0.6 2.1  0.3 8.4  0.5 0.9  0.1
3 133  1.6 3.8  0.2 100  1.3 25  1.6 5.5  0.6 2.3  0.3 7.8  1.3 0.9  0.1
4 134  1.3 3.97  0.3 100  2.3 22.8  5 5.3  1.1 2.2  0.5 6.8  1.9 0.8  0.2
5 134  1.6 4.0  0.3 101  1.9 23.2  4.6 5.3  0.8 2.3  0.5 7.2  1.5 0.8  0.2
6 134  1.8 4.1  0.2 100  2.3 21.6  8.4 4.8  1.3 2.1  0.8 6.0  2.5a 0.7  0.3
Na+, sodium; K+, potassium; Cl, chloride; HCO3, bicarbonate; Ca
++, calcium; Phos, phosphorus; EUN, eﬄuent urea nitrogen; Cr,
creatinine.
aWithin a column, signiﬁcantly diﬀerent from baseline (Time 1) measurement.
Table 4. Mean  standard deviation values of the volume of eﬄuent produced and volume of dialysate, pre- and
postﬁlter replacement ﬂuid used (mL/h) over 6 hours of renal replacement therapy (see Fig 1) in 5 horses along
with the mean  standard deviation calculated creatinine clearance (CrCl), urea reduction ratio (URR), and urea
clearance over time (Kt/V).
Time
(hours)
Eﬄuent
(mL/h)
Eﬄuent
(mL/kg/h)
Dialysate
(mL)
Preﬁlter
(mL)
Postﬁlter
(mL)
CrCla
(mL/min)
CrCla
(mL/kg/min)
URRa
(%) Kt/Va
1 6,352  1,567 11.2  2.1 2,389  60 22,377  608 1,595  391 73.6  16.9 0.1349  0.03 N/A 0.336  0.06
2 6,835  252 12.2  1.1 2,559  94 2,566  94 1,705  57 76.8  9.6 0.1421  0.02 N/A 0.338  0.06
3 6,819  368 12.2  1.1 2,585  140 2,559  141 1,707  81 75.1  12 0.1415  0.03 N/A 0.329  0.06
4 6,598  270 11.8  1.2 2,475  94 2,479  105 1,647  60 63.0  21.0 0.1153  0.04 N/A 0.291  0.11
5 6,654  744 11.8  1.1 2,492  285 2,504  251 1,637  243 68.0  16.2 0.1239  0.02 N/A 0.303  0.05
6 6,317  496 11.3  1.6 2,402  199 2,390  191 1,588  123 56.9  20.8 0.1041  0.04 23.6  7 0.254  0.12
N/A, not applicable.
aSee text for formulas.
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mately 20% lower than the CrCl reported in the
healthy horses of this study.12 In another report,
the estimated CrCl in 2 horses treated with intermit-
tent peritoneal dialysis was 60 L/wk and 80 L/wk.13
Based on the study here, a mean CrCl of 69 mL/min,
6 hour treatment period, and 1 week of treatment (one
6-hour treatment/d) would yield an estimated CrCl of
174 L/wk using RRT. Of note, none of the described
artiﬁcial methods of mimicking kidney function
approaches the eﬃciency of the kidneys in healthy
horses (mean CrCl 2.1 mL/kg/min; range 1.7–2.7 mL/
kg/min) clearly demonstrating that there is no current
substitute for the function of the healthy equine kidney
in an animal of this size.37 Although the CrCl docu-
mented in this study does not approach rates equal to
the healthy horse or smaller patients, the authors of
this study suggest that RRT may help facilitate recov-
ery from ARF, particularly in light of the fact that the
CrCl of CRRT moderately exceeds that of intermittent
or continuous peritoneal dialysis, both of which have
been used successfully to treat ARF in horses.12,13
Urea reduction ratio (URR) represents the percentage
decline in urea concentration during a dialysis session
and is a function of clearance of urea from the blood by
the dialyzer, duration of dialysis treatment, and volume
of distribution of urea in the patient.38 The URR is a
quantitative measurement of urea clearance and is used
as a proxy for adequacy of solute clearance.38 The URR
is inversely correlated with body weight such that URR
in small dogs and cats treated with intermittent hemodi-
alysis ranges from 45 to 95%.21,39–41 In 2 studies in peo-
ple (mean body weight 71 and 79 kg) with ARF treated
with hemodialysis, the mean  SD URR was 54  15
and 63  8%.39,40 The URR has also been used as a
measure of dialysis adequacy in people with end-stage
kidney disease with 1 study suggesting that intensity of
dialysis should result in a URR of  60% to improve
survival.39 Little information is available with regard to
the URR and CRRT; however, in the horses studied
here, the meanURRwas notably lower (24%) than other
species treated with intermittent hemodialysis and was
likely a reﬂection of the slower solute clearance of CRRT
as well as the much larger body weight and low BUN
concentration (ie, minimal concentration gradient of
urea nitrogen between blood and dialysate) of the horses
used in this study. Another variable to consider that may
have impacted the URR is the diuresis created by the
CRI of detomidine; urea clearance may have been
increased by the increased urine output.
Urea clearance over time (Kt/V) describes the fractional
clearance of urea during a hemodialysis treatment while
factoring in patient size. In this formula, K represents urea
clearance (mL/min), whereas Kt represents total solute
removal per time period (K [mL/min] 9 time [min]
patient receives treatment per day). Kt is then normalized
by dividing Kt by the patient’s volume of distribution (V
in mL). Urea is equally distributed throughout all body
ﬂuid compartments, thus the volume of distribution is esti-
mated by total body water in mL (estimated to be 60% of
body weight [kg] in the horse 9 1,000).42 Similar to CrCl
and URR, the overall mean Kt/V in this study (0.308) was
lower than that which was reported in people or small ani-
mals.5,43–45 In general, aKt/V of 1–1.3 is targeted in people
with acute kidney injury and has been reported to provide
acceptable treatment eﬃcacy in people.43–45 Owing to the
large size of the horse relative to people and companion
animals, it is not unexpected that the Kt/V was notably
lower than target values in other species.
It is clear that strict standardization of anticoagulant
administration, quantiﬁcation of adequacy of solute
removal, and dose/intensity of CRRT are not well
established in people.46 However, several recent large
prospective trials in critically ill patients with acute
kidney injury have investigated the optimal intensity of
renal replacement therapy and survival.45–49 In these
studies, there was no diﬀerence in 60- to 90-day sur-
vival in patients receiving lower intensity continuous
venovenous hemodiaﬁltration (eﬄuent ﬂow rate of
20–25 mL/kg/h) as compared with treatment at higher
intensity (eﬄuent ﬂow rate of 35–40 mL/kg/h)45–49;
therefore, the current suggested target dose for CRRT
is 20 mL/kg/h.50 In the study here, the mean eﬄuent
(based on body weight) was approximately half of the
target eﬄuent dose in people, ranging from 11 to
12 mL/kg/h. Based on maximum ﬂow rate limitations
with commercial CRRT machines, higher doses are
not likely possible in horses.
Interpretation of the methods to evaluate treatment
adequacy in horses should be made in light of 2
important variables: (1) horses in this study were
healthy with serum concentrations of urea and creati-
nine within reference intervals, and (2) the mean body
weight of the horses in this study was 544 kg. It is
anticipated that horses with ARF and marked azote-
mia would demonstrate a higher concentration gradi-
ent for diﬀusion of uremic toxins to occur from the
blood to dialysate, thus resulting in higher CrCl,
URR, and urea clearance over time during RRT ses-
sions. The user must also be aware that the commer-
cial equipment available for veterinary use was
designed for people (ie, body weight <100 kg). There-
fore, the eﬃcacy of RRT in people and small animals
is greater than in horses because of their smaller body
weight. For example, based on an average body weight
of a 70 kg person with 5,600 mL blood volume,
approximately 22 minutes of RRT (blood ﬂow rate
140 mL/min) is necessary to process a complete blood
volume exchange.51 In comparison, a 450 kg horse
with 36,000 mL blood volume would take approxi-
mately 144 minutes of RRT (blood ﬂow rate 250 mL/
min) to process the complete blood volume.
As noted previously, indications for instituting RRT in
people include reduced glomerular ﬁltration rates that
result in solute imbalance (eg, azotemia with uremic clini-
cal signs, hyperkalemia [>6 mEq/L], metabolic acidosis
[pH < 7.2] caused by renal failure) or oliguria resulting in
extracellular ﬂuid volume overload (eg, pulmonary
edema) that does not respond to other forms of treat-
ment.14,15 Varying degrees of azotemia, uremic encepha-
lopathy, and other metabolic derangements have been
reported in horses with ARF.9–13,52–56 Urine production
in equine ARF varies ranging from oliguria, frequently
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noted in the early stages of hemodynamically mediated
ARF, to nonoliguria or polyuria; however, anuria is
rare.2,12,13,53,56 The number of published reports and ret-
rospective studies of equine ARF are sparse, but presum-
ably many cases respond to conventional treatment.2,9–
13,52,53 However, numerous reports of equine ARF with
persistent or worsening azotemia, oliguria, or both have
been documented, some of which have prompted clini-
cians to utilize drugs to promote renal perfusion or urine
production (furosemide, mannitol, dopamine) and RRT
(peritoneal dialysis, IHD) to facilitate recovery.2,9–13,53,56
In this study involving healthy horses, the net ﬂuid change
was set to 0; if ﬂuid retention was present in a clinical case
of equine ARF, the CRRT machine could be set to pro-
vide a net ﬂuid loss to reduce ﬂuid retention in the patient.
Furthermore, ﬂuids utilized in RRT can be tailored to spe-
ciﬁc electrolyte compositions to eﬀectively correct
electrolyte derangements such as moderate-to-severe hy-
perkalemia associated with ARF.36 The authors suggest
that given the limited options of advanced treatment for
ARF in horses, RRT is a viable treatment option.
Several limitations of this study should be noted. First,
CRRT in people is typically administered for prolonged
periods of time (ie, days). In the study here, horses were
administered RRT for only 6 hours. While a longer treat-
ment period could have been attempted in this study,
maintaining a horse under light sedation and restraint for
longer than 6 hours may impose undue stress to the horse.
In a clinical case of ARF in a horse, the authors suggest a
treatment period of 6–8 hours per day, followed by a per-
iod or rest, and then recommencement of RRT. Another
limitationwas the fact that the horses were healthy. In ure-
mic patients, bleeding diathesis, as a result of altered plate-
let function and excessive production of prostacyclin and
nitric oxide, may be present.57 Therefore, anticoagulant
dosagemay need to bemodiﬁed in clinical situations based
on the status of patient hemostasis. Despite these limita-
tions, RRT was successfully administered to healthy
horses using a commercially available CRRT machine,
dialysate/replacement ﬂuids, and anticoagulant with mini-
mal changes in monitored vital parameters in healthy
horses. RRT is unlikely to be as eﬃcacious in clearing ure-
mic toxins in horses, as compared with smaller patients,
yet the authors contend that CRRT is worth of consider-
ation as an adjunct treatment in horses withARF.
Footnotes
a AnaSed, Lloyd Laboratories, Shenandoah, IA
b 14 gauge 9 5.25 inch intravenous catheter, Mila International,
Erlanger, KY
c 16 gauge 9 3 inch intravenous catheter, Mila International
d 20 gauge 9 1.5 inch Quickﬂash Radial Artery Catheter, Arrow
International, Reading, PA
e 14 French 9 24 cm split catheter, MedComp, (ASPC24-3),
Harleysville, PA
f Rusch Foley Catheter, Teleﬂex Medical, Kamunting, Malaysia
g Passport 2, Datascope Corp, Mahwah, NJ
h Dormosedan, Pﬁzer Animal Health, Exton, PA
i Sodium Heparin, APA Pharmaceuticals, Exton, PA
j PrismaFlex, Gambro, Lund, Sweden
k M150 Filter, Gambro, Meyzieu Cedex, France
l Plasmalyte, Abbot Laboratories, Chicago, IL
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